Acute Myeloid Leukemia: How Do We Measure Success?
- PMID: 27604228
- DOI: 10.1007/s11899-016-0346-x
Acute Myeloid Leukemia: How Do We Measure Success?
Abstract
The development and approval of novel, effective therapies for acute myeloid leukemia (AML) has lagged behind other malignancies. Judging success of therapy with meaningful endpoints is critical to development of new treatments. Overall survival (OS) has typically been the parameter necessary for regulatory approval of experimental therapy in AML. Herein, we discuss different strategies to define outcomes for patients with AML and their relative challenges.
Keywords: Acute myeloid leukemia; Event-free survival; Overall survival; Therapy.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical